|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C , 1st trimester ; D , 2nd / 3rd trimester
|
|
INDICATIONS:
|
|
Heart failure, congestive |
|
Hypertension, essential |
|
Myocardial infarction |
| |
|
|
SIDE EFFECTS:
|
|
anaphylactoid reactions |
|
angioedema |
|
azotemia |
|
cholestasis |
|
cough |
|
dizziness |
|
dysgeusia |
|
edema |
|
fatigue |
|
headache |
|
hepatic failure |
|
hepatic necrosis |
|
hepatitis |
|
hyperkalemia |
|
hypotension |
|
jaundice |
|
laryngeal edema |
|
metallic taste |
|
orthostatic hypotension |
|
pneumonitis |
|
sinus tachycardia |
|
syncope |
|
teratogenesis |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
aortic stenosis |
|
autoimmune disease |
|
black patients |
|
bone marrow suppression |
|
breast-feeding |
|
cardiomyopathy |
|
cerebrovascular disease |
|
children |
|
collagen-vascular disease |
|
coronary artery disease |
|
dialysis |
|
elderly |
|
heart failure |
|
hyperkalemia |
|
hyponatremia |
|
hypotension |
|
hypovolemia |
|
immunosuppression |
|
low-density lipoprotein apheresis |
|
pregnancy |
|
renal artery stenosis |
|
renal disease |
|
renal failure |
|
|
ADULT DOSE:
|
|
Antihypertensive-Initial: Oral, 10 mg once a day, the dosage being adjusted according to clinical response .
Maintenance: Oral, 20 to 40 mg once a day .
Note: An initial dose of 5 mg should be used in patients who are sodium- and water-depleted as a result of prior diuretic therapy, patients continuing to receive diuretic therapy, or patients with renal failure (creatinine clearance less than or equal to 30 mL per minute). An initial dose of 2.5 mg should be used in patients with a creatinine clearance less than 10 mL per minute. Such patients should be kept under medical supervision for at least two hours after this initial dose (and for an additional hour after blood pressure has stabilized), to watch for excessive hypotension.
Vasodilator, congestive heart failure -Initial: Oral, 5 mg per day, the dosage being adjusted according to clinical response .
Maintenance: Oral, 5 to 20 mg per day.
Note: An initial dose of 2.5 mg per day should be used in patients with hyponatremia or who have moderate to severe renal impairment (creatinine clearance less than or equal to 30 mL per minute).
Acute myocardial infarction-Initial: Oral, 5 mg within 24 hours of onset of an acute myocardial infarction, followed by 5 mg after 24 hours, 10 mg after 48 hours, then 10 mg per day.
Maintenance: Oral, 10 mg per day for six weeks.
Note: In patients with low systolic blood pressure (£ 120 mmHg), an initial dose of 2.5 mg should be used when treatment begins, or during the first three days after the infarction. If hypotension occurs (systolic blood pressure is less than or equal to 100 mmHg), a daily maintenance dose of 5 mg may be given with temporary reduction to 2.5 mg if needed. If prolonged hypotension occurs (systolic blood pressure £ 90 mmHg for more than 1 hour), lisinopril should be withdrawn. |
|
MAXIMUM ADULT DOSE:
|
|
Doses up to 80 mg per day have been used.
|
|
PEDIATRIC DOSE:
|
|
Safety and efficacy have not been established.
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|